A Phase 2b Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis

Inclusion Criteria

• Male or female, 18 years or older.
• Chronic AD as defined by Hanifin and Rajka (1980) that has been present for ?1 year before the screening visit .
• Eczema Area and Severity Index (EASI) score ?16 at the screening and the baseline visit.
• Investigator Global Assessment (IGA) score ?3 (scale of 0 to 4) at the screening and the baseline visit.
• ?10% body surface area (BSA) of AD involvement at the screening and the baseline visit.

Exclusion Criteria

• Treatment with any of the following agents within 4 weeks prior to the baseline visit:
• Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-?, Janus kinase inhibitors, azathioprine, methotrexate, etc.)
• Phototherapy and photochemotherapy (PUVA) for AD.
• Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 1 week prior to the baseline visit.
• Treatment with:
• An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer, prior to the baseline visit.
• Dupilumab within 3 months prior to baseline visit.
• Cell-depleting biologics, including rituximab, within 6 months prior to the baseline visit.
• Other biologics within 5 half-lives (if known) or 16 weeks prior to baseline visit (whichever is longer).
• Use of prescription moisturizers within 7 days of the baseline visit.

Gender

All

Ages

18 Years and older

Accepts Healthy Volunteers

No